PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors - Trial NCT01158300
Access comprehensive clinical trial information for NCT01158300 through Pure Global AI's free database. This Phase 1 trial is sponsored by Pediatric Brain Tumor Consortium and is currently Completed. The study focuses on Brain and Central Nervous System Tumors. Target enrollment is 28 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Pediatric Brain Tumor Consortium
Timeline & Enrollment
Phase 1
Nov 01, 2010
Jan 01, 2015
Primary Outcome
Maximum-tolerated dose,Adverse events
Summary
RATIONALE: PTC299 may stop the growth of tumor cells by blocking blood flow to the tumor.
 
 PURPOSE: This phase I trial is studying the side effects and the best dose of PTC299 in
 treating young patients with recurrent or refractory primary central nervous system tumors.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT01158300
Non-Device Trial